CD40LG and neuroblastoma: The regulatory approval of anti-GD2 for the treatment of neuroblastoma has set the stage for cancer-associated carbohydrate antigens as new class of targets for cancer immunotherapy.15 In this context, the ability of AS/OBI-821 vaccine to induce GH-specific IgM and IgG antibodies, which displayed the biological functions of complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC),5 and the prevalence of GH expression in cancer with limited expression in normal tissues make AS/OBI-821 vaccine a promising new carbohydrate-targeted immunotherapeutics.